{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005442","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2026-08-12T11:31:19+00:00","discovered_at":"2026-08-12T11:35:00.282210+00:00","generated_at":"2026-08-12T11:35:07.715931+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arbutus Q2 net loss $5.1M; receives $178M Moderna payment, plans $230M buyback","bullets":["Q2 revenue fell to $1.0M from $10.7M YoY; net loss of $5.1M ($0.03/share) vs net income of $2.5M in 2025.","Received $178.4M from Moderna settlement in July; owns ~16% of Genevant and expects a dividend.","Board authorized up to $230M share repurchase program, may include tender offer, starting Q3 2026.","Filed international patent lawsuits against Pfizer and BioNTech across 21 countries for LNP technology.","FDA granted Fast Track for imdusiran; alignment on Phase 2b design for chronic hepatitis B."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005442","json":"https://secwatch.observer/filing/0001171843-26-005442.json","markdown":"https://secwatch.observer/filing/0001171843-26-005442.md","text":"https://secwatch.observer/filing/0001171843-26-005442.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326005442/0001171843-26-005442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326005442/f8k_081226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T11:35:07.715931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}